No Data
No Data
Eagle Eye Technology-B (02251.HK): Losses have expanded, focusing on building a matrix of FSG Medical Serv A products.
The company's performance in 2024 was weaker than expected, with reported results for 2024: revenue of 0.156 billion yuan (-23.3% year-on-year), and a net loss attributable to shareholders of 0.255 billion yuan (compared to a loss of 0.133 billion yuan in 2023).
Eagle Eye Technology-B (02251) announced its annual performance, achieving revenue of 0.156 billion yuan, with the usage of myopia prevention AI products reaching 4.025 million times, a year-on-year increase of 352.1%.
Eagle Eye Technology-B (02251) announced the annual performance for the year ending December 31, 2024, during which the group achieved...
AIRDOC-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
AIRDOC-B: DATE OF BOARD MEETING
GF SEC: The recovery of Medical IT Orders in February, pay attention to the subsequent implementation of AI Orders.
With the continuous deepening of AI technology applications and the increasingly sound Medical data security and compliance framework, it is expected that the demand for Medical IT will steadily rise in the next 3-5 years.
Beijing Airdoc Technology Expects 2024 Loss to Widen; Shares Slide 7%